Meta-analysis Of The Effect Of Statins Combined With PCSK9 Inhibitor Evolocumab On Lipid Metabolism

Objective: The aim of this study was to evaluate the efficacy of statins combined with evolocumab,a procrotein converting enzyme(PCSK9),in the treatment of dyslipidemia..Methods: to search Pub Med,EMBASE,the Cochrane Library and CNKI,collect the clinical randomized controlled trials of the efficacy evaluation of statins combined with PCSK9 inhibitor evolcumab compared with statins combined with placebo or Ezetimibe in the treatment of dyslipidemia,and use Revman 5.3 software to conduct meta analysis on the collected data.Results: The nine studies included 33294 subjects.In one study,evolocumab was compared with ezeimib and placebo at the same time.In eight studies,evolocumab and placebo were compared,and ezeib and placebo were included in the same group.Evolocumab and placebo were compared The number of cases in m Ab group was 17336 and 15958,respectively.The results of meta analysis showed that evolocumab significantly reduced the level of LDL-C to 52.09%,95% CI(-58.92,-45.27)compared with placebo or ezeimab.According to the frequency of administration,70-140 mg /week and 280-420 mg / month of evolocumab were analyzed.The results showed that the LDL-C reduction of LDL-C was greater than that of placebo.In some studies,evolocumab also had beneficial effects on other lipids: reducing the levels of non-high density lipoprotein(non-HDL-C),apolipoprotein B(apo B),triglyceride and cholesterol.Conclusion: the combination of statins and evolocumab,an inhibitor of PCSK9,can provide a new choice for LDL-C level still not reaching the standard after intensive statins treatment.